Use of a cocktail of monoclonal antibodies and human complement in selective killing of acute lymphocytic leukemia cells.

作者: Kenichi Sugita , Otto Majdic , Hannes Stockinger , Wolfgang Holter , Ursula Köller

DOI: 10.1002/IJC.2910370305

关键词:

摘要: Autologous remission bone marrow is a potential source of repopulative stem cells after ablative chemoradiotherapy tumor patients. Even with marrow, one major obstacle to use autologous bone-marrow support the danger reinfusing viable cells. This report describes purging protocol human complement, which seems suitable for eliminating acute lymphatic leukemia (ALL) common ALL type. Lysis blasts induced cocktail 3 monoclonal antibodies IgM type (termed VIB-pool). These are directed against CALLA (CD 10) antigen (VIL-AI antibody) and 2 different epitopes CD24 surface structure (VIB-C5 VIB-E3 antibodies). The efficiency was evaluated leukemic cell lines (Reh-6 Nalm-6) blast from Optimal lysis obtained antibody serum concentrations as low 1 microgram/ml 7% respectively. As standard we propose 20-min incubation at room temperature followed by two 30-min incubations 37 degrees C 25% complement. In dye exclusion test 99% in clonogenic assays detecting elimination up 5 logs 99.99% (= 4 logs) were achieved. Treatment VIB-pool complement had no negative effect on growth normal hemopoietic progenitor CFU-GM, CFU-E BFU-E.

参考文章(22)
G Hale, S Bright, G Chumbley, T Hoang, D Metcalf, AJ Munro, H Waldmann, Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement Blood. ,vol. 62, pp. 873- 882 ,(1983) , 10.1182/BLOOD.V62.4.873.873
J. Kersey, D. Vallera, N. Ramsay, L. Filipovich, R. Stong, T. LeBien, R. Youle, D. Neville, P. Beverley, Monoclonal Antibodies for Purging Bone Marrow of Acute Lymphoblastic Leukemia or Graft Versus Host Producing Cells:Antibody Plus Complement or Immunotoxins Minimal Residual Disease in Acute Leukemia. pp. 233- 239 ,(1984) , 10.1007/978-94-009-5670-4_17
S. Sallan, L. Nadler, J. Ritz, R. C. Bast, R. Gelber, C. Maver, P. De Fabritiis, J. Lipton, Elimination of Malignant Clonogenic Cells from Human Bone Marrow Using Multiple Monoclonal Antibodies and Complement Cancer Research. ,vol. 45, pp. 499- 503 ,(1985)
Tucker W LeBien, J. H. Kersey, C. S. Abramson, A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage. Journal of Immunology. ,vol. 126, pp. 83- 88 ,(1981)
L M Nadler, S F Schlossman, J F Daley, M Bates, G Marti, K C Anderson, E Park, B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. Journal of Immunology. ,vol. 131, pp. 244- 250 ,(1983)
John Kersey, Candice Abramson, Guy Perry, Anne Goldman, Mark Nesbit, Kazimiera Gajl-Peczalska, Tucker Lebien, CLINICAL USEFULNESS OF MONOCLONAL- ANTIBODY PHENOTYPING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA The Lancet. ,vol. 320, pp. 1419- 1423 ,(1982) , 10.1016/S0140-6736(82)91326-5
STEVEN J. COLLINS, ROBERT C. GALLO, ROBERT E. GALLAGHER, Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. ,vol. 270, pp. 347- 349 ,(1977) , 10.1038/270347A0
LeeM. Nadler, Leslie Botnick, Robert Finberg, GeorgeP. Canellos, Tak Takvorian, RobertC. Bast, Samuel Hellman, StuartF. Schlossman, ANTI-B1 MONOCLONAL ANTIBODY AND COMPLEMENT TREATMENT IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR RELAPSED B-CELL NON-HODGKIN'S LYMPHOMA The Lancet. ,vol. 324, pp. 427- 431 ,(1984) , 10.1016/S0140-6736(84)92907-6
C. Rosenfeld, A. Goutner, A.M. Venuat, C. Choquet, J.L. Pico, J.F. Dore, A. Liabeuf, A. Durandy, C. Desgrange, G. De The, An effective human leukaemic cell line: Reh European Journal of Cancer. ,vol. 13, pp. 377- 379 ,(1977) , 10.1016/0014-2964(77)90085-8
Keith A. Krolick, Jonathan W. Uhr, Ellen S. Vitetta, Selective killing of leukaemia cells by antibody–toxin conjugates: implications for autologous bone marrow transplantation Nature. ,vol. 295, pp. 604- 605 ,(1982) , 10.1038/295604A0